Breast Cancer (update of QLQ-BR23)

Gender Neutral
Type Module
Testing Phase IV - pending
Principal investigator(s)
Vesna Bjelic-Radisic
Medical University Graz, Department of Obstetrics and Gynecology
Graz, Austria
Study coordinator(s)
Brigitte Bliem
Medical University of Graz
Graz, Austria

Project summary

The standard therapy of breast cancer has been changed, new therapies brought new side effects, therefore different impacts on quality of life are not sufficiently covered by EORTC QLQ BR-23.

Achievements

A phase 3 study was conducted to pretest the provisional module.

Future plans

Ethical approval in May-July 2018 patient recruitment 4-18 months.

For patients

The standard therapy of breast cancer has been changed, new therapies brought new side effects, therefore different impacts on quality of life are not sufficiently covered by EORTC QLQ BR-23.  An update of the module was necessary. Relevant QoL issues related to the new treatment options were generated and pretested with respect to understanding, comprehensiveness and applicability. The phase 3 of the study is completed and in a next step the module will be field-tested in a large international group of patients (phase 4).